The Efficacy of Venlafaxine in Treatment of Depression in Parkinson's Disease

Torun F., Bayulkem K., Torun S. D.

KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.21, no.1, pp.18-23, 2011 (SCI-Expanded) identifier identifier


Objective: Depression is the most common psychiatric disorder appearing in Parkinson's Disease (PD) with an average prevalence rate almost 40-50 %. Selective serotonin and norepinephrine reuptake inhibitors (SNRIs) are currently used in the treatment of depression in patients with PD, but we have not found any studies in the literature regarding this treatment choice. The aim of this prospective study was to investigate the therapeutic efficacy of venlafaxine, which is a SNRI antidepressant, in the treatment of depression in Parkinson's disease.